PODD — Insulet Corp.

Market sentiment is bearish as of 2026-08-27: PODD is down roughly 48.8% YTD, sits below all major moving averages, and the August 5, 2026 guidance reset for U.S. Type 2 utilization/retention spooked investors. Voluntary device corrections and securities class-action exposure have added a credibility discount, even though Q2 revenue grew 23.5% and international revenue surged 35.5%.

Revenue has compounded strongly: quarterly revenue went from $543.9M in Q3 2024 to $706.3M in Q3 2025 and $801.7M in Q2 2026. YoY growth accelerated through 2025, peaking around 34% in Q1 2026, but decelerated to 23.5% in Q2 2026 versus 32.9% in Q2 2025—a real slowdown, not just a blip. Gross margin held around 70% in Q2 2026, while operating margin compressed to 16.2% from 18.7% a year earlier. The most concerning trend is cash flow: Q2 2026 operating cash flow fell to $88.4M from $196.5M in Q2 2025, and free cash flow fell to $59.4M from $173.3M.

As of 2026-08-27, the stock looks cheap on headline multiples: TTM P/E of 26.8x, forward P/E of roughly 22x on consensus FY2026 EPS of $6.50, P/S of 3.25x, and a trailing PEG of 0.45. The 5-year average P/E of 1,140x is useless as an anchor because prior earnings were tiny; the current P/S is far below the 5-year average of 11.4x but that also reflects an earlier hyper-growth phase. Relative to a 20%+ EPS grower with 70% gross margins, 22x forward earnings is not expensive, but the quality/legal overhang justifies a below-market premium.

At $143.41 as of 2026-08-27, the market is paying about 22x forward earnings, which means it is pricing in execution risk, not future growth. If U.S. Type 2 retention stabilizes and full-year estimates hold, even a modest 25x multiple would put fair value near $163. If another guidance cut or legal/quality negative forces consensus EPS down toward $5.50-$6.00, the current multiple will not protect the stock and it could retest the $126 low. The earnings are solid on paper; the market simply does not trust them yet.

As of 2026-08-27, RSI stood at 42.99—weak but not oversold. Price was 2.69% below the 20-day SMA, 6.91% below the 50-day SMA, and 33.5% below the 200-day SMA, so the stock is in a clear downtrend and has not yet built a base. With the 52-week range at $126.40-$354.88, PODD is closer to the low end, but momentum is still negative; I would wait for a reclaim of the 20-day SMA or an RSI move above 50 before treating the chart as turning.

• The broader med-tech sector is in risk-off mode, with IHI down over 10% YTD, pressuring high-multiple device names.
• FDA and regulatory scrutiny of insulin delivery has increased after voluntary product corrections, creating sector-wide caution.
• Interest rates and long-duration growth asset de-rating continue to pressure stocks with multi-year growth narratives.
• Competitive dynamics are intensifying in diabetes tech from Tandem, Medtronic, Abbott, and Dexcom integrations.
• Pharmacy-channel and payer dynamics remain key to Type 2 expansion, especially rebate structures and reimbursement changes.

• Q3 2026 earnings, expected early November 2026, should show whether U.S. Type 2 retention/utilization is stabilizing.
• August 31, 2026 lead-plaintiff deadline in the securities class action could refocus the legal overhang.
• EVOLVE clinical study and Omnipod 5 international launches in Spain, the Middle East, and other markets could reignite the growth narrative.
• Any update restoring U.S. Omnipod growth confidence could drive a sentiment reversal given how far the stock has fallen.

• Further voluntary corrections or manufacturing quality issues could damage brand trust and invite regulatory enforcement.
• The securities class-action litigation creates a financial overhang and management distraction.
• U.S. Type 2 patient retention/under-utilization could be structural rather than transient, forcing additional guidance cuts.
• Free cash flow deterioration—Q2 2026 FCF fell 66% YoY—could signal working capital, inventory, or remediation costs building.
• Competitive pricing pressure in the pharmacy channel could erode gross margins over time.

As of 2026-08-27, PODD is not a clear buy yet, but the risk/reward is starting to balance. The franchise is still growing revenue 23.5% with 70% gross margins, yet the stock is down ~49% YTD because of a U.S. Type 2 guidance reset, quality corrections, and litigation risk. At roughly 22x forward earnings, much of the bad news is priced in, but I would want at least one quarter of stabilizing U.S. retention data before calling this a high-conviction long.

I applied a 24x forward P/E to the consensus next-fiscal-year EPS of $6.50, which is a justified multiple for a 20%+ EPS grower with 70% gross margins, discounted for U.S. Type 2 retention risk, product-correction history, and litigation overhang. This yields $156.07, which is above the current price but below the analyst consensus target.